The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
© 2023. The Author(s)..
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-fatal cardiovascular diseases. It is based on sex, age, smoking habits, systolic blood pressure, non-high-density lipoprotein cholesterol, and European geographical region of cardiovascular risk. The SCORE2/SCORE2-OP algorithm translated more patients (50.2%) to the high-very high cardiovascular risk category than the previous SCORE (25.3%). Patients with a high to very high SCORE2/SCORE2-OP risk showed a significantly higher incidence rate of AOEs (69.2% vs. 46.5%, p < 0.001). The older SCORE was less specific in estimating AOEs in patients classified as low-intermediate risk (69.8 vs. 54.2%). In multivariate analysis, no associations were found between AOEs and gender, age, and type or dose of tyrosine kinase inhibitor. Only the SCORE2/SCORE2-OP risk was confirmed as a significant predictive factor (p = 0.028; hazard ratio = 2.2; 95% confidence interval = 1.1-4.5). Patients with AOEs required, in most cases, imaging diagnostic tests, additional drugs, and sometimes invasive procedures, increasing access to visits and hospital management. This real-life study suggested that the SCORE2 and SCORE2-OP charts could help identify cardiovascular fragility in CML patients providing them with more attention and a proper TKI selection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Annals of hematology - 103(2024), 2 vom: 28. Jan., Seite 427-436 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mulas, Olga [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4340891KFS |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00277-023-05556-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36503620X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36503620X | ||
| 003 | DE-627 | ||
| 005 | 20240122231944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-023-05556-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM36503620X | ||
| 035 | |a (NLM)38012435 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mulas, Olga |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-fatal cardiovascular diseases. It is based on sex, age, smoking habits, systolic blood pressure, non-high-density lipoprotein cholesterol, and European geographical region of cardiovascular risk. The SCORE2/SCORE2-OP algorithm translated more patients (50.2%) to the high-very high cardiovascular risk category than the previous SCORE (25.3%). Patients with a high to very high SCORE2/SCORE2-OP risk showed a significantly higher incidence rate of AOEs (69.2% vs. 46.5%, p < 0.001). The older SCORE was less specific in estimating AOEs in patients classified as low-intermediate risk (69.8 vs. 54.2%). In multivariate analysis, no associations were found between AOEs and gender, age, and type or dose of tyrosine kinase inhibitor. Only the SCORE2/SCORE2-OP risk was confirmed as a significant predictive factor (p = 0.028; hazard ratio = 2.2; 95% confidence interval = 1.1-4.5). Patients with AOEs required, in most cases, imaging diagnostic tests, additional drugs, and sometimes invasive procedures, increasing access to visits and hospital management. This real-life study suggested that the SCORE2 and SCORE2-OP charts could help identify cardiovascular fragility in CML patients providing them with more attention and a proper TKI selection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arterial occlusive event | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Nilotinib | |
| 650 | 4 | |a Ponatinib | |
| 650 | 4 | |a Prophylaxis | |
| 650 | 4 | |a SCORE2 | |
| 650 | 7 | |a ponatinib |2 NLM | |
| 650 | 7 | |a 4340891KFS |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridazines |2 NLM | |
| 700 | 1 | |a Abruzzese, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Luciano, Luigiana |e verfasserin |4 aut | |
| 700 | 1 | |a Iurlo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Attolico, Immacolata |e verfasserin |4 aut | |
| 700 | 1 | |a Castagnetti, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Galimberti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifacio, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Annunziata, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Gozzini, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Orlandi, Ester Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Stagno, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Binotto, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Pregno, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Fozza, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Loi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Trawinska, Malgorzata Monika |e verfasserin |4 aut | |
| 700 | 1 | |a De Gregorio, Fiorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Albano, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Iezza, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Baratè, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Scaffidi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Elena, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Giai, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Scalzulli, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a La Nasa, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Caocci, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 103(2024), 2 vom: 28. Jan., Seite 427-436 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:2 |g day:28 |g month:01 |g pages:427-436 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-023-05556-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 2 |b 28 |c 01 |h 427-436 | ||